New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 7, 2014
07:42 EDTEPZMEpizyme initiates pediatric MLL-r proof-of-concept study for leukemia candidate
Epizyme initiated a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene. This Phase 1b study is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of 3 months and 18 years and to provide a preliminary assessment of efficacy. Expected data disclosure date is in 2H14.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
11:48 EDTEPZMEpizyme executives get lucrative options as stock craters, TheStreet says
During the first week of January, Epizyme priced a secondary stock offering at $9 per share while its stock was trading near $15 per share, noted TheStreet's Adam Feuerstein, who said "no other biotech company doing an equity financing at the same time offered as steep a discount." Subsequently, the company disclosed that stock option grants priced at $8.98 were awarded to the company's top four executives, making "Epizyme executives look tone deaf by awarding themselves attractively priced stock options while their shareholders suffer," said Feuerstein. Reference Link
February 8, 2016
08:01 EDTEPZMEpizyme says tazemetostat granted orphan drug designation by FDA
Subscribe for More Information
February 7, 2016
14:13 EDTEPZMEpizyme's tazemetostat receives orphan designation for malignant rhabdoid tumors
Subscribe for More Information
February 2, 2016
07:15 EDTEPZMCanaccord to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use